[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-neoplasm":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,89,115,152,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100636237","effect-of-high-flow-nasal-cannula-oxygen-therapy-on-hypoxemia-in-pediatric-sedated-bronchoscopy-100636237",false,"NCT07563075","Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy","Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* 1 year ≤ age ≤ 6 years,\n* Weight ≥ 10 kg,\n* Undergoing elective sedated bronchoscopy,\n* Expected procedure duration ≤ 45 minutes,\n* Written informed consent obtained from the subject's legal guardian.\n\nExclusion Criteria:\n\n* preoperative SpO₂ \\\u003C 95% on room air,\n* Already sedated and tracheally intubated,\n* Known history of pneumothorax, known congenital or acquired upper airway abnormalities (e.g., nasopharyngeal structural anomalies), or history of difficult airway,\n* Coagulation disorders or predisposition to oral\u002Fnasal bleeding, mucosal injury, or space-occupying lesions,\n* Severe cardiac insufficiency (\\\u003C 4 METs), severe renal insufficiency (requiring dialysis), diagnosed severe hepatic insufficiency, Increased intracranial pressure, or ASA classification ≥ IV,\n* Allergy to propofol or sufentanil,\n* Multiple traumatic injuries,\n* Current participation in another clinical trial,\n* Other conditions deemed unsuitable by the investigator.","ALL","1 Year","6 Years",{"count":20,"type":21},430,"ESTIMATED","INTERVENTIONAL",[24],"NA","Due to children's lower oxygen reserves and higher oxygen consumption, sedation can easily lead to respiratory adverse events such as hypoxemia. It has been reported that the incidence of hypoxemia during pediatric bronchoscopy is high, highlighting that hypoxemia in pediatric painless bronchoscopy is an urgent problem requiring a solution. High-flow nasal cannula (HFNC) oxygen therapy delivers heated and humidified breathing gas with a precisely controllable oxygen concentration, at flow rates exceeding the patient's peak inspiratory flow, directly via unsealed nasal prongs. It is a simple, comfortable, effective, and non-invasive respiratory support method that has been widely adopted in clinical practice. However, the effectiveness of HFNC in pediatric sedation remains unclear. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxemia during sedated bronchoscopy in pediatric patients.",[27,28,29],"Hypoxemia","Pneumonia","Pulmonary Neoplasm",[31,27,32,33,34],"Bronchoscopy","Sedation","Pediatric","High-flow nasal cannula","NOT_YET_RECRUITING","2026-04-28",{"date":38,"type":39},"2026-05-01","ACTUAL",{"date":41,"type":21},"2026-04-01",{"date":43,"type":21},"2027-03-31",{"name":45,"class":46},"Zhejiang University","OTHER",4,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":73,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100634739","enhanced-copd-management-in-suspected-lung-cancer-patients-100634739","NCT07543601","Enhanced COPD Management in Suspected Lung Cancer Patients","Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention","ECHELON","Inclusion Criteria:\n\n* Undergoing diagnostic evaluation for suspected lung cancer\n* Spirometry showing obstructive airflow limitation (FEV₁\u002FFVC \\\u003C 75 % or FEV₁ \\\u003C 80 %, and no reversibility) at the first outpatient visit at the lung cancer evaluation\n\nExclusion Criteria:\n\n* Presence of significant comorbidities that may interfere with diagnostic procedures or spirometry\n* Pregnant or breastfeeding women","18 Years",{"count":58,"type":21},280,[24],"Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates.\n\nThis study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle.\n\nThe findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.",[62,63,64,65,66,29,67,68,69,70,71,72],"COPD (Chronic Obstructive Pulmonary Disease)","Lung Cancer (Diagnosis)","Lung Neoplasm Malignant","Lung Carcinoma","Pulmonary Neoplasms","Pulmonary Cancers","Pulmonary Cancer","Pulmonary Carcinoma","COPD","COPD - Chronic Obstructive Pulmonary Disease","Airflow Obstruction, Chronic",[74,75,76,77],"Invesigation","Evaluation","Diagnostic Work-up","Diagnostic Pathway","RECRUITING","2026-04-15",{"date":81,"type":39},"2026-04-22",{"date":83,"type":39},"2026-03-06",{"date":85,"type":21},"2027-06-30",{"name":87,"class":46},"Ditte Krag-Hansen",1,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":88},"100479346","phase-4-erector-spinae-block-for-thoracic-surgery-100479346","NCT05521789","Erector Spinae Block for Thoracic Surgery","Erector Spinae Blocks for Thoracic Surgery","Inclusion Criteria:\n\n* pulmonary resection\n* 18\\\u003Cage\\\u003C90\n\nExclusion Criteria:\n\n* pleurodesis\n* decortication\n* emergent surgery\n* local anesthetic allergy\n* intraoperative complication (inadvertent hemorrhage or conversion to open surgery)\n* bilateral pulmonary resection","90 Years",{"count":98,"type":21},70,[100],"PHASE4","The aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.",[29,68,103,104,105],"Thoracic Diseases","Thoracic Cancer","Thoracic Neoplasms","2026-02-23",{"date":108,"type":39},"2026-02-25",{"date":110,"type":39},"2022-07-22",{"date":112,"type":21},"2027-07-21",{"name":114,"class":46},"George Washington University",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":139,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":88},"100505180","precision-lung-cancer-survivorship-care-intervention-100505180","NCT05857995","Precision Lung Cancer Survivorship Care Intervention","Precision Lung Cancer Survivorship Care Intervention: A Randomized Controlled Trial Serving Rural Survivors and Communities","KYLEADSII","Inclusion Criteria:\n\n* Have been diagnosed with lung cancer\n* Reside in a rural county as determined by a Rural Urban Continuum Code (RUC) of 4 or higher\n* Be at least 18 years of age or older\n* Be able to communicate effectively in English\n\nExclusion Criteria:\n\n* Have significant psychiatric disturbance that requires a higher level of care\n* Have substance abuse\u002Fdependence that requires a higher level of care\n* Are participating in another lung cancer survivorship care intervention\n* Have previously participated in the Kentucky LEADS Lung Cancer Survivorship Care Program",{"count":124,"type":21},300,[24],"The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.",[128,29,129,130,131,132,133,68,134,135,67,136,137,66,138],"Lung Cancer","Neoplasms, Lung","Neoplasms, Pulmonary","Neoplasm, Pulmonary","Cancer, Lung","Cancers, Lung","Cancer, Pulmonary","Cancers, Pulmonary","Cancer of the Lung","Cancer of Lung","Lung Cancers",[140,141,142,143],"Survivorship","Quality of Life","Behavioral Oncology","Psychosocial Oncology","2026-02-19",{"date":106,"type":39},{"date":147,"type":39},"2024-08-16",{"date":149,"type":21},"2028-03-31",{"name":151,"class":46},"Jerod L Stapleton, PhD",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":161,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":88},"100547761","the-natural-history-and-biological-study-of-pulmonary-recurrent-respiratory-papillomatosis-prrp-100547761","NCT06412172","The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)","Inclusion Criteria:\n\n* History of HPV-associated Recurrent Respiratory Papillomatosis\n* Has pulmonary lesions\n\nExclusion Criteria:\n\n* None","99 Years",{"count":160,"type":21},100,"OBSERVATIONAL","Recurrent respiratory papillomatosis (RRP) is an orphan disease that affects approximately 20,000 people in the United States and is caused by infection with human papillomavirus (HPV) types 6 and 11. Since RRP is an orphan disease, it is an understudied disease entity with correspondingly few treatment options. The investigators hypothesize that by understanding the biology of RRP and the failed host immune responses against HPV, novel and rational therapies can be developed. This study will examine the genetic and immunologic alterations found in these rare tumors and distant metastatic involved sites (such as the lung) in patients diagnosed with RRP.",[164,29],"Recurrent Respiratory Papillomatosis","2025-08-08",{"date":167,"type":39},"2025-08-12",{"date":169,"type":39},"2024-04-15",{"date":171,"type":21},"2030-04-15",{"name":173,"class":46},"Massachusetts General Hospital",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":161,"phases":4,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":88},"100558045","rarecells-molecular-biomarkers-for-early-detection-of-lung-cancer-100558045","NCT06546007","Rarecells Molecular Biomarkers for Early Detection of Lung Cancer","Clinical Study To Evaluate the Sensitivity of Circulating Iset® by Rarecells Molecular Biomarkers for Early Detection of Lung Cancer","BioMolCTC","Inclusion Criteria:\n\n1. Male or female aged between 35 and 85 years\n2. Patient diagnosed with resectable lung cancer (by imaging and\u002For pathological examination) not yet treated for this cancer.\n3. Patient capable of giving free, informed, and express consent\n\nThe assessment of successful elected surgery implies, but is not limited to, the following:\n\n* Exclusion of detectable extra thoracic and distant metastases\n* Determination of the presence or absence of superior mediastinal lymph node metastases\n* Definition of the histologic or cell type, whenever possible\n* Evaluation of operative risk\n\nExclusion Criteria:\n\n1. Patient diagnosed and\u002For treated previously for lung cancer or another cancer, regardless of duration\n2. Patient treated with neoadjuvant treatment\n3. Pregnant women\n4. Patient presenting psychiatric or neurological disorders preventing them from understanding the research","35 Years","85 Years",{"count":185,"type":21},50,"Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.\n\nThis study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.",[128,29],[189,190,191,192],"Circulating tumor cells","Lung cancer","Circulating tumor DNA","Pulmonary neoplasm","2025-06-10",{"date":195,"type":39},"2025-06-11",{"date":197,"type":39},"2024-11-13",{"date":199,"type":21},"2025-10-01",{"name":201,"class":202},"Rarecells Diagnostics SAS","INDUSTRY"]